Neoleukin Therapeutics (NASDAQ:NLTX) Shares Down 0.7%

Share on StockTwits

Neoleukin Therapeutics (NASDAQ:NLTX)’s share price traded down 0.7% during trading on Thursday . The company traded as low as $2.91 and last traded at $2.93, 1,200 shares traded hands during mid-day trading. A decline of 97% from the average session volume of 39,169 shares. The stock had previously closed at $2.95.

Separately, ValuEngine downgraded Neoleukin Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, September 12th.

The firm has a fifty day moving average price of $2.96.

An institutional investor recently bought a new position in Neoleukin Therapeutics stock. California Public Employees Retirement System bought a new stake in Neoleukin Therapeutics (NASDAQ:NLTX) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 56,800 shares of the company’s stock, valued at approximately $162,000. California Public Employees Retirement System owned approximately 0.20% of Neoleukin Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 59.26% of the company’s stock.

Neoleukin Therapeutics Company Profile (NASDAQ:NLTX)

Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies using protein design technology. The company's lead product candidate is NL-201, a computationally-designed de novo protein therapeutic for the treatment of IL-2/IL-15 cancer immunotherapy. It also engages in research activities for the treatment of autoimmunity and allergy.

Further Reading: What are the benefits of a balanced fund?

Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.